Imunon Inc. is a clinical-stage biotechnology company at the forefront of developing innovative immune-mediated therapies targeting cancer and infectious diseases. Leveraging its proprietary INFECT platform, Imunon aims to enhance immune response mechanisms, facilitating effective tumor eradication. With a diversified pipeline of therapeutics across multiple clinical stages and strategic collaborations that bolster its operational expertise, Imunon is strategically positioned to revolutionize immunotherapy, offering the potential to significantly enhance treatment outcomes for patients while shaping the future of the biopharmaceutical landscape.
| Revenue (TTM) | 125,000 |
| Gross Profit (TTM) | -172,216 |
| EBITDA | $-14.52M |
| Operating Margin | 0.00% |
| Return on Equity | -768.00% |
| Return on Assets | -124.40% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $0.86 |
| Price-to-Book | 1.91 |
| Price-to-Sales (TTM) | 17.94 |
| EV/Revenue | 4.004 |
| EV/EBITDA | 0.91 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $4.20M |
| Float | $3.61M |
| % Insiders | 5.45% |
| % Institutions | 11.99% |
Volatility is currently expanding
Translational and clinical data reinforce IMNN-001's potential to unlock IL-12's anti-tumor power in ovarian cancer within a highly safe, proprietary mechanism
Preliminary data reinforces IMNN-001 immunotherapy's potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial
On track for enrollment of 80 participants by Q1 2027 Trial is supported by Phase 2 results showing significant improvement in overall survival in women with newly diagnosed advanced ovarian cancer Novel immunotherapy technology demonstrating unprecedented IL-12 safety profile and extraordinary Phase 2 efficacy LAWRENCEVILLE, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the independent Data Monitoring Committee (iDMC) has recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with standard of care (SoC) neoadjuvant and adjuvant chemotherapy (N/ACT) in women with newly diagnosed advanced ovarian cancer.
LAWRENCEVILLE, N.J., June 22, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of IMUNON, will present at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on Thursday, June 25, 2026, at 12:00 p.m. ET.
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports IMUNON's Highly Anticipated Phase 3 OVATION 3 Study of IMNN-001 in advanced ovarian cancer LAWRENCEVILLE, N.J., June 04, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company has entered into definitive agreements with expected aggregate gross proceeds to the Company in the amount of $10 million.
Imunon, Inc. (IMNN) Q1 2026 Earnings Call Transcript
IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in women newly diagnosed with ovarian cancer Enrollment in the Phase 3 OVATION 3 Study of IMNN-001 is expected to be completed by Q1 2029, supported by remarkable Phase 2 data showing significant overall survival improvement FDA has reviewed and is aligned with Phase 3 protocol, confirms path to BLA Filing Company to hold conference call today at 11:00 a.m. ET LAWRENCEVILLE, N.J.
LAWRENCEVILLE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a.m.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IMNN and any ticker you trade — then tracks every position and per-strategy win rate.
